Magic mushroom therapy for PTSD tested in groups

NCT ID NCT07506395

Recruiting now Symptom relief Sponsor: University of New Mexico Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether giving psilocybin (the active ingredient in magic mushrooms) in a group setting is safe and feasible for people with PTSD. 36 participants, including veterans, first responders, and survivors of sexual violence, will receive two group dosing sessions. Researchers will monitor side effects and measure changes in PTSD symptoms, depression, and anxiety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If this works, it could point toward a new, group-based therapy option for PTSD that may ease symptoms like anxiety and depression.
What could go wrong: This is a very early, small Phase 1 trial with only 36 participants. It focuses on safety and feasibility, not proof of effectiveness. Psilocybin can cause temporary psychological distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTSD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTSD

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Interdisciplinary Substance Use and Brain Injury (ISUBI)
RECRUITING

Albuquerque, New Mexico, 87131, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.